secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeMD, Inc. (LFMD)
CIK:        0000948320
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001493152-26-009380
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026
--------------------------------------------------------------------------------

- FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).
- Q4 2025 revenue $46.9M (+4% YoY); adjusted EBITDA $4.8M (+348% YoY).
- Launched oral Wegovy post-year-end; >80% of new weight management patients using branded therapy; Q1 sign-ups at record levels.
- Ended 2025 with $36.8M cash, no debt; guides to annualized revenue >$250M and adj EBITDA >$25M by Q4 2026.
- Benefits infrastructure on track to cover ~220M Americans in Q2 2026; women's health seeing strong early growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/948320/000149315226009380/0001493152-26-009380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/948320/000149315226009380/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer